TAM Receptor

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1561 BMS-777607 <1 mg/mL 47 mg/mL <1 mg/mL
S2841 R428 (BGB324) <1 mg/mL 6 mg/mL <1 mg/mL
S4001 Cabozantinib malate (XL184) <1 mg/mL 100 mg/mL <1 mg/mL
S7342 UNC2250 <1 mg/mL 2 mg/mL <1 mg/mL
S7846 TP-0903 <1 mg/mL 3 mg/mL 1 mg/mL
S8573 Sitravatinib (MGCD516) <1 mg/mL 100 mg/mL 100 mg/mL
S8570 RXDX-106 (CEP-40783) <1 mg/mL 10 mg/mL 2 mg/mL
S7576 UNC2025 100 mg/mL 25 mg/mL 8 mg/mL
S7638 LDC1267 <1 mg/mL 100 mg/mL 2 mg/mL
S7325 UNC2881 <1 mg/mL 92 mg/mL 5 mg/mL
S7669 NPS-1034 <1 mg/mL 100 mg/mL 4 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. Phase 1/2.


R428 (BGB324)

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).


Cabozantinib malate (XL184)

Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.



UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.



TP-0903 is a potent and selective AXL Inhibitor with IC50 of 27 nM.


Sitravatinib (MGCD516)

Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.


RXDX-106 (CEP-40783)

RXDX-106 (CEP-40783) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/MET inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.



UNC2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.



LDC1267 is a highly selective TAM kinase inhibitor with IC50 of <5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. Displays lower activity against Met, Aurora B, Lck, Src, and CDK8.



UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.



NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.